Beam Therapeutics Inc. (BEAM) Latest Stock News & Headlines …
WEBGet the latest Beam Therapeutics Inc. (BEAM) stock news and headlines to help you in your trading and investing decisions.
Beam Therapeutics Inc. (BEAM) Stock Price, News, Quote
WEBFind the latest Beam Therapeutics Inc. (BEAM) stock quote, history, news and other vital information to help you with your stock trading and investing.
Beam Therapeutics Inc (BEAM) Reports Strong Year-End …
WEBFeb 27, 2024 · BEAM, a pioneering biotechnology firm specializing in precision genetic medicines through base editing, has reported a solid financial position and promising progress in its clinical programs.
Beam Therapeutics Inc (BEAM) Stock Price & News - Google Finance
WEBGet the latest Beam Therapeutics Inc (BEAM) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
BEAM Stock Quote Price and Forecast | CNN
WEBJun 27, 2023 · View Beam Therapeutics, Inc. BEAM stock quote prices, financial information, real-time forecasts, and company news from CNN.
BEAM Stock Price | Beam Therapeutics Inc. Stock Quote (U.S.: …
WEB2 days ago · BEAM | Complete Beam Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
Beam Therapeutics Highlights Progress Across Base ... - Markets …
WEBJan 8, 2024 · BEAM-302 is a potentially best-in-class liver-targeting LNP formulation of base editing reagents designed to correct the PiZ allele, the most common gene variant associated with severe AATD ...
Beam Therapeutics Announces Portfolio Prioritization and …
WEBOct 19, 2023 · Prioritize development of its ex vivo and in vivo sickle cell disease programs, including BEAM-101, its Engineered Stem Cell Antibody Paired Evasion (ESCAPE) non-genotoxic conditioning strategy, and in vivo delivery to hematopoietic stem cells (HSCs).
Beam Therapeutics Announces First Patient Dosed in Phase 1/2 …
WEBSep 5, 2023 · The ongoing Phase 1/2 trial of BEAM-201 is a multicenter, open-label study evaluating safety and efficacy in patients with relapsed/refractory T-ALL/T-LL. T-ALL/T-LL is a highly aggressive blood cancer arising from malignant transformation of T cell precursors that has few treatment options.
Beam Therapeutics Inc. Common Stock (BEAM) Stock Price, Quote, News …
WEBBeam Therapeutics Inc. Common Stock (BEAM) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.
Skip to content